Beta cell dysfunction in patients with acute myocardial infarction but without previously known type 2 diabetes: a report from the GAMI study

[1]  B. Zinman,et al.  A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[2]  H. Yagi,et al.  Glucose intolerance is common in Japanese patients with acute coronary syndrome who were not previously diagnosed with diabetes. , 2005, Diabetes care.

[3]  A. Brazzale,et al.  Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test , 2005, Diabetologia.

[4]  W. Tamborlane,et al.  The normal glucose tolerance continuum in obese youth: evidence for impairment in beta-cell function independent of insulin resistance. , 2005, The Journal of clinical endocrinology and metabolism.

[5]  Masafumi Matsuda,et al.  beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. , 2005, The Journal of clinical endocrinology and metabolism.

[6]  K. Choi,et al.  0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(1):175–180 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2004-1795 Inflammation, Insulin Resistance, and Glucose Intolerance in Acute Myocardial Infa , 2022 .

[7]  Y. Seino,et al.  Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. , 2004, Diabetes research and clinical practice.

[8]  L. Rydén,et al.  Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. , 2004, European heart journal.

[9]  Roberto Ferrari,et al.  The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. , 2004, European heart journal.

[10]  L. Rydén,et al.  Abnormal glucose tolerance – a common risk factor in patients with acute myocardial infarction in comparison with population‐based controls , 2004, Journal of internal medicine.

[11]  I. Godsland,et al.  Loss of beta cell function as fasting glucose increases in the non-diabetic range , 2004, Diabetologia.

[12]  C. Padovani,et al.  Pancreatic β-cell defects in women at risk of type 2 diabetes , 2004 .

[13]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[14]  C. Padovani,et al.  Pancreatic beta-cell defects in women at risk of type 2 diabetes. , 2004, Diabetes research and clinical practice.

[15]  B. Zinman,et al.  A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. , 2002, Diabetes care.

[16]  A. Hamsten,et al.  Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study , 2002, The Lancet.

[17]  G. Shulman,et al.  Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β‐cell dysfunction , 2002, European journal of clinical investigation.

[18]  C. Berne,et al.  Proinsulin Is an Independent Predictor of Coronary Heart Disease: Report From a 27-Year Follow-Up Study , 2002, Circulation.

[19]  R. Bergman,et al.  Increased proinsulin levels and decreased acute insulin response independently predict the incidence of type 2 diabetes in the insulin resistance atherosclerosis study. , 2002, Diabetes.

[20]  R. Pratley,et al.  The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus , 2001, Diabetologia.

[21]  Andrea Mari,et al.  A Model-Based Method for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test , 2001 .

[22]  S. Kahn,et al.  Abnormal glucose tolerance and increased risk for cardiovascular disease in Japanese-Americans with normal fasting glucose. , 2001, Diabetes care.

[23]  C. Bogardus,et al.  Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. , 2001, Diabetes care.

[24]  L. Groop,et al.  Insulin secretion and insulin sensitivity in diabetic subgroups: studies in the prediabetic and diabetic state , 2000, Diabetologia.

[25]  J S Alpert,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.

[26]  K. Tokuyama,et al.  Assessment of insulin sensitivity and insulin secretion from the oral glucose tolerance test in nonobese Japanese type 2 diabetic patients: comparison with minimal-model approach. , 2000, Diabetes care.

[27]  M. Stumvoll,et al.  Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. , 2000, Diabetes care.

[28]  C. Bogardus,et al.  The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. , 1999, The Journal of clinical investigation.

[29]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[30]  S. Yusuf,et al.  The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.

[31]  B. Howard,et al.  Lowering fatty acids potentiates acute insulin response in first degree relatives of people with Type II diabetes , 1998, Diabetologia.

[32]  R. Bergman,et al.  Ability of alternative indices of insulin sensitivity to predict cardiovascular risk: comparison with the "minimal model". Insulin Resistance Atherosclerosis Study (IRAS) Investigators. , 1998, Annals of epidemiology.

[33]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[34]  R. Schwartz,et al.  Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. , 1998, The Journal of clinical endocrinology and metabolism.

[35]  S. Haffner,et al.  Are risk factors for conversion to NIDDM similar in high and low risk populations? , 1997, Diabetologia.

[36]  J. Sturis,et al.  Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. , 1996, The New England journal of medicine.

[37]  S. Haffner,et al.  Decreased Insulin Secretion and Increased Insulin Resistance Are Independently Related to the 7-Year Risk of NIDDM in Mexican-Americans , 1995, Diabetes.

[38]  J. Levy,et al.  U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.

[39]  G. Dailey,et al.  Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. , 1995, JAMA.

[40]  M. Nauck,et al.  Gut hormones and diabetes mellitus. , 1992, Diabetes/metabolism reviews.

[41]  H. Yki-Järvinen.  Glucose toxicity. , 1992, Endocrine reviews.

[42]  Irene A. Stegun,et al.  Handbook of Mathematical Functions. , 1966 .